再生医学技术研究商TETROUS完成650万A轮融资，为未来增长确保了额外资本-动脉网

TETROUS®, INC. SUCCESSFULLY CLOSES FINANCING ROUND, SECURING ADDITIONAL CAPITAL FOR FUTURE GROWTH

CISION 等信源发布 2025-03-10 19:00



可切换为仅中文







LOS ANGELES

洛杉矶

，

March 10, 2025

2025年3月10日

/PRNewswire/ -- Tetrous, Inc., a

/PRNewswire/ -- Tetrous, Inc.，一家

Sherman Oaks

谢尔曼奥克斯

start up focused on bone-to-tendon healing following orthopedic surgery, is pleased to announce the successful closure of its Series A financing round, raising a total of

专注于骨科手术后骨腱愈合的初创公司，欣然宣布其A轮融资成功结束，共筹集资金

$6,500,000

6,500,000美元

. This round of financing was a Reg D offering available to accredited investors. It attracted a diverse group of investors, including a significant investment (over 50% of the raise) from strategic partners including our

此轮融资是一次符合Reg D规定的融资，面向合格投资者。它吸引了包括我们的战略合作伙伴在内的多元化投资者群体，其中战略合作伙伴的投资占了此次融资的50%以上。

USA

美国

and Australian manufacturing and distribution partners, as well as investments from the management team, and existing shareholders. The round was expanded twice from the initial

以及澳大利亚的制造和分销合作伙伴，还有管理团队和现有股东的投资。此轮融资从最初的规模扩展了两次。

$5,000,000

5000000美元

target due to overwhelming interest and support from existing investors, strategic partners and new investors.

由于现有投资者、战略合作伙伴和新投资者的极大兴趣和支持，目标得以实现。

继续阅读

Investors were enthusiastic about how Tetrous is redefining bone to tendon repair, addressing a major unmet need for biological regeneration of the anatomic structure that provides proper transmission of tensile load from soft tissues to bone, ie. the enthesis. The enthesis is a significant point of failure in rotator cuff repairs, which have a reported failure rate of 13%-94%!.

投资者对Tetrous如何重新定义骨到肌腱的修复充满热情，解决了解剖结构生物再生的重大未满足需求，该结构能够实现软组织到骨骼的适当张力传递，即“骨腱连接处”。骨腱连接处是肩袖修复中的一个主要失效点，其报告的失败率高达13%-94%！

excited to further our partnership as they continue to prove that biologic healing is the future of bone-tendon healing

我们很高兴进一步加强合作，因为他们不断证明生物愈合是骨腱愈合的未来

Post this

发布这个

The Series A funds are being used to increase the company's market penetration, develop further clinical data showing the improvement in outcomes for patients, and expand surgical applications of the company's patented technology, including for hip, knee, ankle and elbow procedures with existing and new product offerings..

A轮融资正被用于增加公司的市场渗透率，进一步开发临床数据以展示患者治疗效果的改善，并扩大公司专利技术在外科手术中的应用，包括现有和新产品在髋关节、膝关节、踝关节和肘关节手术中的应用。

'We are thrilled with the success of this financing round and the confidence our existing shareholders and strategic partners have placed in us,' said

“我们对本轮融资的成功以及现有股东和战略合作伙伴给予我们的信心感到非常激动，”

Bradley Patt

布拉德利·帕特

, PhD., CEO of Tetrous. 'This funding is enabling us to further enhance our product offerings, broaden our reach, and continue to deliver exceptional value to our customers. It's All About the Enthesis.'

博士，Tetrous公司首席执行官。“这笔资金使我们能够进一步提升我们的产品供应，扩大我们的覆盖范围，并继续为我们的客户提供卓越的价值。一切都与肌腱附着点有关。”

'I am excited to further our partnership with Tetrous as they continue to prove that biologic healing is the future of bone-tendon healing' said Simon Berry, CEO of Tetrous Manufacturing and Distribution partners Australian Biotechnologies (

“我对我们与Tetrous的合作关系进一步发展感到兴奋，因为他们不断证明生物愈合是骨腱愈合的未来。” Tetrous制造和分销合作伙伴澳大利亚生物技术公司首席执行官Simon Berry说道。

Sydney, Australia

悉尼，澳大利亚

) and Origin Biologics (

）和起源生物制品（

Las Vegas, NV

内华达州拉斯维加斯

, USA) and Director of ABT Healthcare, a

，美国）和ABT医疗保健公司的董事，

Sydney

悉尼

based Investment Trust. 'They have demonstrated an impressive vision for growth, and we are thrilled to support their continued success.'

基于投资信托。 “他们展现了一个令人印象深刻的增长愿景，我们很高兴支持他们的持续成功。”

The EnFix

恩菲克斯

family of allograft products are designed to enhance healing at the enthesis, where failure often occurs. The implants are 100% demineralized bone fiber (DBF), providing osteoinductivity and osteoconductivity, resulting in optimal biologic performance with minimal disruption to current surgical techniques..

同种异体移植物产品系列旨在增强骨腱连接处的愈合，那里通常是容易发生失效的地方。这些植入物由100%脱矿骨纤维（DBF）制成，具有骨诱导性和骨传导性，能够在对现有手术技术影响最小的情况下实现最佳的生物性能。

About Tetrous, Inc.

关于Tetrous公司

Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery.

Tetrous公司成立于2019年，利用下一代先进技术进行运动医学中的韧带修复。EnFix产品系列的首批产品是用于肩袖修复的EnFix RC和EnFix TAC。Tetrous源于为脊柱手术开发的技术。

The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 150,000 implants in spine applications. Tetrous enjoys significant IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics Company. .

公司正在推广并拓展该技术在运动医学领域的全新应用。其核心技术已在脊柱应用领域超过15万件植入物中得到使用。Tetrous对其EnFix系列产品的知识产权保护具有显著优势，拥有多个已授权专利，并且还从ISTO生物公司TheraCell获得了用于其运动医学产品中的脱矿骨纤维技术的独家许可。

About ABT Healthcare

关于ABT医疗保健

ABT Healthcare is based in

ABT医疗保健公司总部位于

Sydney, Australia

悉尼，澳大利亚

and is a private investment fund that invests in early stage medtech companies. ABT Healthcare fund invests internationally across multiple market segments. The Fund is led by

是一家投资于早期医疗技术公司的私人投资基金。ABT医疗保健基金在国际上跨多个市场领域进行投资。该基金由

Lawrence Myers

劳伦斯·迈尔斯

，

Jerome Goldberg

杰罗姆·戈德伯格

and

和

Simon Berry

西蒙·贝瑞

. Inquiries can be made to

. 可以进行查询